Form 4: aTyr Pharma Inc. Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Nancy Denyes, General Counsel of aTyr Pharma Inc., sold 899 shares of common stock to cover tax obligations following the vesting of restricted stock units (RSUs).

Summary

• Nancy Denyes, the General Counsel of aTyr Pharma Inc., reported transactions involving the company's common stock.
• On February 3, 2025, 2,687 shares were acquired upon the vesting of restricted stock units (RSUs) granted on February 3, 2022.
• On February 4, 2025, 899 shares were sold at a price of $3.78 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Denyes directly owns 26,555 shares of aTyr Pharma Inc.
• The reported transactions also include the vesting of 2,687 restricted stock units, which convert into common stock on a one-for-one basis.
• The RSUs vest in four equal annual installments beginning on February 3, 2023, and will fully vest on February 3, 2026.
• The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation and tax obligations. There's no indication of significant positive or negative implications for the company.

Positives

• The vesting of RSUs indicates a form of compensation and alignment of interests between the executive and the company's performance.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it's a common practice.

Risks

• The accelerated vesting of RSUs upon a change of control could create additional expenses for the company in such an event.

Future Outlook

The RSUs will continue to vest in equal annual installments until February 3, 2026.

Industry Context

Executive stock transactions are common in the pharmaceutical industry as part of compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's value.

Comparison to Industry Standards

• RSU grants are a typical component of executive compensation in biotech companies like aTyr Pharma.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize RSUs as part of their executive compensation packages.
• The vesting schedules and terms, such as accelerated vesting upon change of control, are also standard practices in the industry.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders if it creates downward pressure on the stock price, although the volume is relatively small.

Key Dates

Keywords

aTyr Pharma, ATYR, Form 4, Nancy Denyes, RSU, Restricted Stock Units, Insider Trading, Beneficial Ownership, General Counsel, Executive Compensation